{"entity":{"id":"nct05607953","kind":"trial","name":"Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma","aka":[],"tldr":"A phase 1 trial of Nelitolimod run by TriSalus Life Sciences, Inc., active, not recruiting.","summary":"Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma is a phase 1 interventional study registered as NCT05607953 by TriSalus Life Sciences, Inc., with 60 participants planned, started 2023-03-01, primary completion expected 2027-09. Conditions recorded: Locally Advanced Pancreatic Adenocarcinoma. Interventions recorded: SD-101, anti-PD-1.","status":"active","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT05607953","url":"https://clinicaltrials.gov/study/NCT05607953"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["nelitolimod"],"companies":["trisalus-life-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05607953","phase":"1","setting":"A Phase 1/1b Pressure Enabled Regional Immuno-Oncology Study of Pancreatic Retrograde Venous Infusion of SD-101 Alone and With Checkpoint Blockade for Locally Advanced Pancreatic Ductal Adenocarcinoma","sponsor":"TriSalus Life Sciences, Inc.","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05607953/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"nelitolimod","kind":"drug","name":"Nelitolimod","route":"/drugs/nelitolimod/"}],"company":[{"id":"trisalus-life-sciences","kind":"company","name":"TriSalus Life Sciences","route":"/companies/trisalus-life-sciences/"}]}}